US Stock MarketDetailed Quotes
TNFA TNF Pharmaceuticals
- 1.190
- +0.040+3.48%
Close Jan 3 16:00 ET
- 1.220
- +0.030+2.52%
Post 20:01 ET
3.28MMarket Cap-0.09P/E (TTM)
1.250High1.160Low41.66KVolume1.250Open1.150Pre Close49.52KTurnover1.75%Turnover RatioLossP/E (Static)2.76MShares6.45052wk High0.20P/B2.84MFloat Cap1.05052wk Low--Dividend TTM2.39MShs Float6469632.000Historical High--Div YieldTTM7.83%Amplitude1.050Historical Low1.188Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
TNF Pharmaceuticals Stock Forum
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
Thursday, 19th December at 9:15 am
Fully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated with sarcopenic muscle deterioration
Collaboration partner to use AI and machine learning to identify targeted patient pool
Potential entry into high growth GLP-1 market valued at nearly $50 bill...
📊⚡️📊
Tnf Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
1 MINUTE AGO, 9:10 AM EDT
VIA BUSINESSWIRE
Prevail Partners, LLC investment priced at more than a 40% premium to market
Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO with hundreds of clinical trials over a decade
TNF Pharmaceuticals fully funded for clinical trials for next two years
No comment yet